Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Clinical Trials Drug Safety Drug Pricing Weight Loss Cancer Treatment Weight Loss Drugs Drug Regulation Medications

GSK Beats Q2 Estimates and Launches £1.9 Billion Efficiency Programme

The company says the savings will free capital to speed late-stage drug development as it keeps 2026 guidance and expands UK R&D.

Argenx to Buy Forte Biosciences for $2.2 Billion

FDA Advisory Panel Narrowly Backs Compounding of Six Unapproved Peptides

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

Stories older than 24h

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

Study Finds Small Increased Hair‑Loss Risk with GLP‑1 Drugs

FDA Advisers Narrowly Recommend Allowing Six Unapproved Peptides for Compounding

FDA Approves First Over-the-Counter Tylenol–Naproxen Combination Pill

FDA Approves Lytenava, First Ophthalmic Bevacizumab for Wet AMD

Sanofi Confirms Intermittent U.S. Supply of Lantus SoloStar Pens

EU Regulators Back AstraZeneca’s Trixeo for Asthma

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

FDA Advisers Recommend BPC-157 for Pharmacy Compounding

Manufacturer Recalls Generic Zyrtec Over Possible Ranitidine Contamination

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

Lakewood-Amedex Says Nu-3 Did Not Induce Resistance in Lab Tests as Stock Soars

Novo Nordisk Sues Eli Lilly Over Alleged Misleading GLP‑1 Ads

New Studies and Policy Pilots Push GLP‑1 Drugs into Wider Use as Cost and Safety Questions Grow

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

Samsung Biologics Launches SFr1.46 Billion Cash Bid for PolyPeptide